Filing Details
- Accession Number:
- 0001209191-21-056733
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-17 19:04:08
- Reporting Period:
- 2021-09-16
- Accepted Time:
- 2021-09-17 19:04:08
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1679363 | Morphic Holding Inc. | MORF | Pharmaceutical Preparations (2834) | 473878772 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1805908 | Peter Linde | C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-16 | 10,378 | $0.00 | 15,272 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-16 | 100 | $64.29 | 15,172 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-09-16 | 3,276 | $66.48 | 11,896 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-09-16 | 624 | $67.00 | 11,272 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit (RSU | Disposition | 2021-09-16 | 10,378 | $0.00 | 10,378 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-09-16 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
- Includes 294 shares of Common Stock acquired under the issuer's employee stock purchase plan on August 31, 2021.
- Represents the aggregate number of shares sold by the reporting person to cover taxes and fees due upon the release and settlement of the RSUs. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.89 to $66.8825 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.915 to $67.105 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The RSU vests 50% on March 16, 2021 and the remaining 50% vests on September 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.
Billionaire Hedge Funds
